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ABSTRACT
Small extracellular vesicles (sEVs) from mesenchymal stromal/stem cells (MSCs) are transiting rapidly
towards clinical applications. However, discrepancies and controversies about the biology, functions,
and potency of MSC-sEVs have arisen due to several factors: the diversity of MSCs and their
preparation; various methods of sEV production and separation; a lack of standardized quality
assurance assays; and limited reproducibility of in vitro and in vivo functional assays. To address
these issues, members of four societies (SOCRATES, ISEV, ISCT and ISBT) propose specific harmoniza-
tion criteria for MSC-sEVs to facilitate data sharing and comparison, which should help to advance the
field towards clinical applications. Specifically, MSC-sEVs should be defined by quantifiable metrics to
identify the cellular origin of the sEVs in a preparation, presence of lipid-membrane vesicles, and the
degree of physical and biochemical integrity of the vesicles. For practical purposes, new MSC-sEV
preparations might also be measured against a well-characterized MSC-sEV biological reference. The
ultimate goal of developing these metrics is to map aspects of MSC-sEV biology and therapeutic
potency onto quantifiable features of each preparation.
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Introduction
Mesenchymal stromal cells (MSCs) have widely docu-
mented therapeutic efficacy in many pre-clinical mod-
els of immunological and degenerative diseases and
a record of safety in human patients [1–11]. Although
MSCs were initially called “mesenchymal stem cells”
and thought to act therapeutically as stem cells via
cellular differentiation and cell replacement, it is now
apparent that effects of MSCs are mediated mainly by
paracrine factors. Consequently, the stem cell nature of
MSCs has been challenged, and they may be more
appropriately labelled mesenchymal stromal cells or
even “medicinal signalling cells” [12]. Furthermore,
increasing and compelling evidence suggests that
MSCs exert many if not most of their paracrine effects
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through the release of extracellular vesicles (EVs), vesi-
cles of roughly 50–1000 nm in diameter that are
secreted by all cell types [13]. In particular, small EVs
(sEVs, 50 to 200 nm diameter), harvested using differ-
ent protocols from cell culture supernatants of MSCs
grown under diverse culture conditions, have been
reported to be therapeutically efficacious in various
preclinical models [13,14]. Accordingly, MSC-sEVs
have emerged as promising therapeutic agents that
are proposed for testing in clinical trials [13,15]. In
light of the diversity of sources and separation methods
for MSC-sEVs, validated metrics and functional ana-
lyses are required for better characterization of MSC-
sEV preparations to facilitate comparisons across dif-
ferent preparations.
A key to the rapid translation of MSC-sEVs from
bench to bedside is their derivation from MSCs, which
have already been tested extensively in the clinic and
proven to be generally safe. To date, almost 1000 clinical
trials1 have been registered to assess administration of
MSCs derived from a variety of sources, including bone
marrow (BM), adipose tissue (AD), cord blood (CB), and
others. In general, MSCs have a well-established safety
profile in patients. Nevertheless, to date, only a few MSC
products have been approved for market. This might be
related to the lack of therapeutic efficacy observed in
some clinical trials as well as to the heterogeneity of
MSC products prepared by different laboratories.
Diverse strategies of MSC isolation and expansion from
different tissues are used, and standardization across
groups is largely absent. To facilitate the development of
MSCs as therapies, the International Society for Cell and
Gene Therapy (ISCT), formerly known as the
International Society for Cellular Therapy, distilled basic
features of human MSCs into a set of minimal suggested
criteria [16]. Specifically, MSCs are plastic adherent fibro-
blastic cells with the “trilineage potential” of osteogenic,
chondrogenic and adipogenic differentiation capabilities.
Furthermore, they express the cell surface markers CD73,
CD90, and CD105, and do not express haematopoietic
and endothelial antigens (CD14 or CD11b, CD19 or
CD79α, CD34, CD45, HLA-DR) [16]. Notwithstanding
the lack of defining complex functional properties, the
minimal ISCT criteria help to exclude cell preparations
that are not MSCs or are contaminated with non-MSCs.
To enable the development of MSC-sEVs as thera-
peutics, it is critical that similar standardized criteria be
developed to define and qualify the human “MSC-sEV
preparation“ (In this document, we use the term ”pre-
paration” because absolute separation of EVs from
other cell culture supernatant components is likely
unachievable with current techniques. Furthermore,
co-isolated non-sEV components may contribute to
observed therapeutic effects.) Currently, most MSC-
EV preparations are characterized according to the
Minimal Information for Studies of EVs (MISEV2014),
published by the International Society for Extracellular
Vesicles (ISEV) in 2014 [17]. MISEV2014 recommends
specific criteria for definition and classification of EVs
including presence of several characteristic markers
and depletion of presumed non-EV markers, quantita-
tion, and single-vesicle visualization. MISEV2014 was
recently updated and expanded to MISEV2018 [18],
with broad input from members of ISEV, including
the ISCT Exosome Working Group.
Thus, the ISCT minimal criteria provide guidance
for MSCs, and the MISEV recommendations are
a framework for defining and characterizing EVs of
all sizes and morphologies, and from many cell types
and biological sources, some of them with great hetero-
geneity. For example, EVs in biological fluids originate
from many distinct cell types and display a wide range
of phenotypes. Although both criteria are helpful for
characterizing MSC-sEV preparations, they are insuffi-
cient to define MSC-sEVs as a unique entity that is
distinguishable from non-MSC-sEVs. Furthermore, the
existing criteria do not provide guidance on functional
testing of the biological activities of MSC-sEVs.
We suggest that the MSC-sEV field should therefore
build on the ISCT suggested definition of MSCs and
the broad MISEV criteria for EVs to define MSC-sEV
preparation-specific criteria for therapeutic applica-
tions. These new criteria must encompass the potential
diversity of independent MSC-sEV preparations, aris-
ing from the heterogeneity of MSCs by culture and
origin as well as different EV preparation and separa-
tion protocols. Possibly, each manufacturing procedure
will generate unique MSC-EV preparations [14].
Since regimented global standardization of MSC and
MSC-sEV production is unlikely, defining the final
product by physical, biochemical, and functional attri-
butes will be necessary. Clear guidelines must be
balanced with flexibility in the choice of the manufac-
turing process and facilitate data sharing and compar-
ison between independently generated MSC-sEV
products. The overall need, then, is to define MSC-
sEV preparations physically, biochemically, and
functionally by quantifiable features and using
reproducible and standardized assays.
Major questions to answer:
(1) What is an MSC? Are all ISCT criteria relevant?
(2) What are the key features of MSCs that are
likely to also define an sEV preparation as ori-
ginating from MSCs?
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(3) Do MSC-sEV fractions contain non-MSC-sEVs?
What are the likely sources of such non-MSC-
EVs? How can non-MSC-EVs in MSC-sEV pre-
parations be discriminated from MSC-EVs, and
must they be removed?
(4) What is an MSC-sEV preparation as opposed to
an MSC-origin protein, RNA or lipid particle
preparation?
(5) What is the purity of the MSC-sEV preparations?
(6) How to measure integrity of MSC-sEVs in
a preparation?
(7) Which functions do MSC-sEV preparation need
to fulfil to be considered biologically and ther-
apeutically active?
Mesenchymal stromal/stem cells: definitions
and considerations
The definition of MSC-sEV preparations begins with
the MSCs, which are highly heterogeneous cells. Here,
we adopt as the starting point of discussion the mini-
mal defining criteria of human MSCs established by the
Mesenchymal and Tissue Stem Cell Committee of the
ISCT [16]. These criteria state that:
First, MSC must be plastic-adherent when maintained
in standard culture conditions. Second, MSC must
express CD105, CD73 and CD90, and lack expression
of CD45, CD34, CD14 or CD11b, CD79alpha or CD19
and HLA-DR surface molecules. Third, MSC must
differentiate to osteoblasts, adipocytes and chondro-
blasts in vitro.
In general, the ISCT definition is extremely useful in
providing a common reference for defining MSCs;
however, the criteria represent a rudimentary defini-
tion that serves more to eliminate cells that are not
MSCs rather than to define cells that are MSCs.
However, these basic parameters were established in
2006 and no longer represent the totality of knowledge
about biological activities and mechanisms of action
that correlate with therapeutic potency of MSCs, such
as immunomodulation, inhibition of fibrosis, or facil-
itating the proliferation of neighbouring cells or release
of EVs. Based on the original criteria, it is difficult to
predict the therapeutic potency of an MSC preparation
or the reproducibility of potency in independent pre-
parations. More investigations are needed to identify
additional MSC-defining criteria, keeping in mind that
increasing awareness of MSC complexity may make
a single definition elusive. To enhance therapeutic
reproducibility of MSCs, different aspects of the man-
ufacturing process should be considered (Table 1).
Improved robustness of the MSC criteria may be
achieved by re-examining the necessity of certain
MSC surface markers, the necessity of the differentia-
tion potential into all three lineages, and also further
definition and clarification of biological activities and
reproducibility and reliability. There is a growing
recognition that biological activities will be different
for different clinical applications, and that MSCs
respond to and are shaped by local inflammatory con-
ditions. As such, it may be desirable to focus more on
biological activities and less on the traditional sug-
gested criteria, particularly the necessity for osteogenic,
chondrogenic and adipogenic differentiation potential.
Defining MSCs as a cell type is different from defining
MSCs as the source of sEVs. For example, it is possible
that prolonged culture of MSCs might compromise
trilineage potential but not the characteristics and
potential therapeutic efficacy of derived sEVs.
Based on the points discussed above, we propose
that the minimal information required of MSCs as
the cell source of MSC-sEVs should include:
(1) Specification of the tissue source from which
MSCs are isolated (i.e. CB, AD, BM);
(2) Confirmation of at least one of the three lineage
potentials, which should be sufficient to discri-
minate MSCs from fibroblasts, which share
many MSC features but seem to lack therapeutic
activities, and to verify the source of MSC-sEVs
as a therapeutic product;
(3) Definition of source cells as fresh or primary
MSCs or as modified (e.g. immortalized)
MSCs; and
(4) Functional testing of the final MSC-sEV pre-
paration to ascertain if the MSC is capable of
producing functional sEVs.
MSC and MSC-EV production
The release of sEVs is now considered to be one of the
mediators of the therapeutic activities of MSCs [13].
sEVs prepared from in vitro MSC cultures are widely
reported to display therapeutic activities that recapitu-
late those of MSCs in various in vitro functional assays
and in related pre-clinical disease models [19,20].
Table 1. Factors to be considered during the MSC manufactur-
ing process.
1. Tissue source of the MSCs
2. Age of donor and age of the MSCs (passage number or perhaps
doubling time)
3. Donor-to-donor variability and previous pathological conditions
4. Allogeneic versus autologous sources
5. Procedures of MSC isolation
6. Heterogeneity within the MSC culture
7. Preconditioning via addition of proinflammatory cytokines and/or
cultivation under hypoxic conditions.
8. Genetic modification or immortalization of MSCs
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However, it is possible that sEVs produced from static
MSC culture may act differently from sEVs released by
MSCs after administration in vivo. MSCs that produce
therapeutically active sEVs in vitro may not produce
active sEVs in vivo, and vice versa. In addition,
although the current view is that most therapeutic
effects of MSCs occur through paracrine mechanisms,
mainly sEVs, non-paracrine actions of MSCs in vivo
cannot be excluded. Therefore, features that qualify
MSCs as therapeutically active in vivo may not neces-
sarily qualify MSCs as producers of active sEVs in vitro.
Defining better those attributes of sEVs produced by
MSCs in any given condition will allow development of
tools, for example engineered MSCs, that reliably and
reproducibly provide the desired sEV products under
appropriate conditions. For example, MSCs identified
as producers of functional sEVs in vitro could be
immortalized as a monoclonal stable EV-producing
cell line to improve batch-to-batch reproducibility of
sEVs. However, immortalization may have potential
safety concerns that would require mitigation. Unlike
primary cells with limited lifespan, immortalized cell
lines are highly amenable to extensive and intensive
“omics” characterization such as genomic, transcrip-
tomic, proteomic, etc. Additionally, it has been shown
that functionality of MSC-EVs may be retained after
immortalization. For example, after myc-mediated
immortalization, MSCs continued to produce cardio-
protective sEVs [21]. Importantly, MYC protein was
not detected in the sEVs. The myc-immortalized MSCs
were karyotypically stable, expressed the typical MSC
surface antigens and retained two of the trilineage
potentials.
Extracellular vesicles: definitions and
considerations
For definition of EVs, MISEV2014 [17] and the updated
MISEV2018 [18] are the consensus and basis for discus-
sion. As vesicles released by cells, EVs are delimited by
a lipid bilayer membrane and are incapable of self-
replication. MISEV2014 recommends that studies of
EVs should include general characterization, including
detection of transmembrane and luminal proteins and
depletion of presumed cellular or extracellular non-EV
proteins. Quantitation and single-particle characteriza-
tion should be performed by methods including but not
limited to sizing and counting by particle tracking tech-
niques, imaging by electron microscopy, and advanced
flow cytometry. MISEV2018 provides additional gui-
dance in six major areas: i) nomenclature, ii) collection
and pre-processing of fluids for EV extraction, iii) EV
preparation and concentration, iv) EV characterization,
v) functional studies and vi) reporting.
Nomenclature
The term “sEVs” is the best descriptor for the target
population of therapeutic MSC-EVs that we discuss
here. “Small” denotes a population ranging in diameter
from around 50 nm to around 200 nm. EVs are fre-
quently classified generically as “exosomes,” “microve-
sicles,” or by a variety of other terms without strict
consideration of definitions. However, the term “exo-
some” commonly refers to a specific class of sEV
formed by the endosomal system [22,23], in contrast
with “ectosomes” (microvesicles, microparticles) that
bud from the plasma membrane [24,25] or other simi-
larly sized EVs with unknown biogenesis [26].
Specifically, intraluminal vesicles (ILVs) are released
into the extracellular space as exosomes when the mul-
tivesicular body (MVB) fuses with the plasma mem-
brane. While exosomes are generally thought to be
smaller than microvesicles, the two EV types cannot
be differentiated by size alone, as their respective size
ranges overlap. To classify sEVs as “exosomes” requires
evidence of an endosomal biogenesis pathway.
Similarly, to prepare a pure MSC-exosome population,
separation, and characterization protocols would be
required to deplete non-endosome-origin vesicles
from a heterogeneous population, and to verify this
removal. These requirements remain experimentally
challenging to fulfil at this time and is of academic
rather than of clinical interest. In the clinical setting,
it is more important that the MSC-sEV preparations
can be manufactured reproducibly and confer thera-
peutic activities that can be confirmed by robust and
adequate in vitro and in vivo models while avoiding
significant side effects [15]. Since physical separation of
EVs by biogenesis is unrealistic, the term “sEV” is
recommended, which is agnostic to the site of subcel-
lular origin. This term also derives from recent recom-
mendations that EVs be classified by physical
characteristics or isolation method [18,27]. For exam-
ple, EVs that pass through a 0.22 µm filter or are
pelleted at 100,000 x g are generally smaller than 200
nm in diameter and could be classified as sEVs or
a 100k fraction, respectively. While such classification
provides little information on the biology of EVs, it is
practical and enabling as it defines an EV population
that could be universally prepared.
For clarity and to align with the recent recommenda-
tions, we use the term “MSC small EVs (sEVs)” to
describe bilipid membrane vesicles of roughly 50–200
nm in diameter and that are released by MSCs.
4 K. W. WITWER ET AL.
Collection and pre-processing of cell culture
conditions media for EV preparation
The process of producing MSC-sEVs is a major con-
sideration in developing standardized criteria to define
and qualify human MSC-sEV preparations for clinical
applications. To apply and test MSC-sEVs in clinical
studies, a scalable and GMP-compatible manufacturing
process is necessary. The choice of production steps
depends on the quantity needed (batch size), and an
acceptable degree of reproducible purity, identity,
safety, and stability of the final product must be con-
firmed by quality testing. Influence of storage condi-
tions should also be considered.
Cell production
Cell density and 2D vs bioreactor culture
Cell density in 2D culture is well known to affect cell
behaviour and the nature of the secretome. Cells seeded at
lower density have been reported to produce more sEVs
per cell, and this release seems to decline as confluence is
reached [28] although it is not clear if this is a universal
observation. Replicative ageing of the culture (senes-
cence) may also modulate sEV production or alter sEV
efficacy. To scale MSC-sEV production, bioreactors may
be required. Three main bioreactor types are currently
available, each uniquely affecting sEV-producing MSCs:
bioreactors with expanded 2D surfaces, hollow fibre-
based bioreactors, and stirred-tank bioreactors (in
which MSCs must be grown on appropriate microcar-
riers) [29]. Although each has been used for MSC expan-
sion, their impact on sEV production and function
requires further investigation. Well-established growth
conditions may not be transferable from classical static
cultures to bioreactors, necessitating optimization of cul-
ture conditions. However, 3D bioreactors are advanta-
geous as they are more amenable to monitoring of cell
number, viability, morphology and proliferation, and in
providing for a more uniform distribution of nutrients
and oxygen [30].
Cell culture medium components
MSCs, like other mammalian cells, are easily grown in
culture withmedia supplemented with fetal bovine serum
(FBS) as an energy source. However, to facilitate approval
of therapeutic applications, xenogenic components
should be eliminated at least during the sEV production
and harvest phase. Hence, human serum or platelet lysate
(hPL) has been substituted for FBS [31–33]. However,
like FBS, both serum and hPL are themselves rich sources
of EVs or EV-like particles that will co-purify with sEVs
produced by theMSCs. These exogenous EVs are likely to
be safe, as evidenced by the well-established safety of EV-
rich transfusion products, and could even contribute to
therapeutic effects directly or acting as co-factors. Indeed,
MSC-sEVs used for successful treatment of a graft versus
host disease (GvHD) patient [34] contained a large popu-
lation of hPL vesicles. Since identically prepared, hPL
vesicle-containing MSC-sEV preparations exerted the
same therapeutic effects in a murine ischaemic stroke
model as MSCs [35], there is currently no evidence that
hPL vesicles negatively affect therapeutic activities of
MSC-EV preparations. As hPL is generally safe, a subset
of hPL such as hPL-vesicles should be considered to be
safe as well [36]. Still, exogenous sEVs or sEV-like parti-
cles could conceivably dilute or block some effects of
MSC-sEVs. It is thus necessary to establish whether exo-
genous vesicles support or counteract specific MSC-sEVs
therapeutic functions, or whether they can be considered
functionally neutral.
To eliminate exogenous EVs
MSCs could be grown in serum-free (defined) medium
or with serum or hPL that has been depleted of EVs.
Several protocols for EV depletion have been devel-
oped, achieving variable degrees of depletion.
Standard centrifugation and ultrafiltration protocols
for serum depletion have been used [37,38], as well as
tangential flow filtration (TFF) [3]. Importantly, fibri-
nogen/fibrin depletion is an apparent prerequisite for
hPL-EV depletion using filtration-based methods
(including tangential flow filtration), as clotted hPL
components such as fibrin polymers can block filter
pores. To this end, an efficient depletion method for
fibrinogen and fibrin aggregates has been described
[39]. Some culture systems that involve circulation of
fluids through molecular weight cut-off filters may also
permit culture with non-EV-depleted components,
since EVs and large macromolecules in culture media
reservoirs will have little or no access to the cell culture
compartment [40].
Both serum-free and EV-depleted culture options
should be critically evaluated while addressing at least
three important considerations. First, components of
serum or hPL may persist for some time in the culture
after changing to defined conditions, as evidenced by
studies of extracellular RNAs [41]. Second, the stress of
a switch to serum-free or depleted medium may alter
cellular programs [42]. Cells may require gradual acclima-
tization to the new conditions. Third, energy source star-
vation is also known to stimulate EV production by some
cells, at least in the short term, andmay alter themolecular
content of released EVs or EV-like particles. Due to these
impacts of the culture conditions, MSC-sEVs produced
under different culture conditions may have different
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biological features. To identify a scaled MSC-sEV produc-
tion strategy, the composition and functionality of
obtained MSC-sEVs must be investigated carefully to
ensure the quality and biological activities of MSC-sEV
samples.
EV separation and concentration
Drawbacks of legacy methods
Variations on differential ultracentrifugation have been
the most widely used EV separation and concentration
method [43]. However, ultracentrifugation has several
drawbacks that make it an unlikely choice for large-
scale MSC-sEV purifications, especially for therapeutic
applications. Ultracentrifugation does not result in
highly pure EVs. Although serial washes can improve
purity, they also reduce yield [44]. sEV aggregation and
poor resuspension have been reported after ultracen-
trifugation [45], and disruption may also occur. Finally,
ultracentrifugation is not scalable: it is time-consuming
for the volumes that can be processed.
Commercial “kit-based” EV separation methods
Commercial products advertised as specific for EVs or
even EV subtypes such as exosomes have proliferated
in recent years as the EV research field has grown.
While some of these products are well described and
even potentially GMP-compliant, for many, the exact
principle of the separation method is not stated, and
the identity of proprietary matrices and other reagents
is unknown. It is thus difficult to assess safety or how
components of the systems might contribute to possi-
ble EV actions. Unless GMP compliance has been
demonstrated, and proprietary additives are revealed
by suppliers of commercial kits to the pharmaceutical
manufacturers to assess clinical usability and safety of
ingredients, the use of such kits to produce EVs for
clinical use is presently unrealistic.
Polyethylene glycol/polymer-based EV enrichment
Precipitation by “salting out” with polyethylene glycol
(PEG) or other polymers is an effective way to reduce
volume and thus enrich EVs in a reproducible and
scalable manner [46]. While ultracentrifugation can
be performed for only up to approximately 500 mL
culture medium per run (depending on rotor and
buckets), the lower-speed centrifugation required to
pellet PEG precipitates can be done for up to several
litres per run. Each run is also shorter for PEG
precipitates. Because of abundant co-precipitates,
however, PEG-precipitated EVs should not be con-
sidered pure preparations [46]. Also, removal of PEG
and other contaminants by wash steps and UC re-
pelleting may be necessary for some applications.
Nevertheless, PEG-precipitated MSC-sEVs have
already been used in a clinical investigation [34,46],
and MSC-sEVs concentrated by PEG exerted the
same effects in an ischaemic stroke model as corre-
sponding cells. Thus, the procedure does not appear
to interfere with MSC-sEV activity, and co-isolated
materials do not appear to negatively affect sEV
function [35].
Size-based fractionation
Size-based fractionation methods such as size exclu-
sion chromatography (SEC) and tangential flow fil-
tration (TFF) have gained increasing recognition
and adoption as GMP-compatible and highly scal-
able technologies by researchers [47–49]. These
methods are faster and easier to implement than
legacy methods, while at the same time producing
EVs of comparable or superior purity and/or func-
tional activity [46,50]. Conditioned media with high
protein content (e.g. serum- or hPL-supplemented
media) may clog pores, especially in the case of
fibrin formation from concentrated, unprocessed
hPL. In this case, clotting can be induced in advance
and clotted components removed [39]; however,
pre-processing serum or hPL may also change MSC-
supportive properties. Apart from these considera-
tions, these methods are considered scalable and
time efficient, allowing a high degree of process
standardization.
For additional information on EV separation,
we refer the reader to the MISEV2018 criteria
and references cited therein [18]
Characterization
For objective evaluation of MSC-sEV preparations
independent of the manufacturing process, quantifiable
metrics are needed to measure the key defining and
biologically important parameters of MSC-sEVs.
Several questions arise.
When can an sEV preparation be described as an
MSC-sEV preparation?
As a minimum prerequisite, MSC-sEV preparations must
derive from supernatants of MSCs that largely fulfil the
ISCT minimal criteria, as discussed above. The use of
different MSC sources, culture conditions and media, and
EV-harvesting strategies, however, could introduce signifi-
cant variations inMSC-sEV preparations. Therefore, using
a single definition to describe all MSC-sEV preparations
would classify many different products under one
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umbrella. It is rather unlikely that all MSC-sEV prepara-
tions display the same therapeutic activities in different
disease models. To avoid underclassification, MSC-sEV
preparations could be classified according to their manu-
facturing process. However, since most laboratories use
unique protocols, such an approach could lead to over-
classification. With no elegant solution and the unlikeli-
hood of a standard MSC-EV production protocol, the
terms “MSC-EVs” or “MSC-sEVs” will for now continue
to cover EV-containing products derived from MSCs.
However, MSC-sEV preparations from MSCs that are
grown in media supplemented with human or non-
human serum or hPL, may contain non-MSC-EVs. As
discussed above, these non-MSC-sEVs may confer func-
tional properties on MSC-sEV preparations, acting addi-
tively, synergistically, or even antagonistically to MSC-
sEVs. Ideally, the ratio of non-MSC-EVs to MSC-EVs
should be documented and the biological activities of the
non-MSC-EVs defined. To do so, MSC-EVs must be dis-
criminated from non-MSC-EVs. Among the three features
of MSCs in the ISCT suggested minimal criteria for MSCs,
the surface antigens are logically the most immediately
detectable features that could be transferred to EVs. Thus,
antigens like CD73 and CD105might be used to identify at
least a subset of MSC-sEVs. In contrast, serum or hPL-
derived sEVs are expected to display platelet or haemato-
poietic cell markers that are not present on MSCs, such as
CD34 and CD45, the endothelial marker CD31, the red
blood cell marker Glycophorin A, or the platelet markers
CD41, CD42, and P-selectin. Very recently, we could dis-
criminate hPL-EVs andMSC-EVswith anti-CD9 and anti-
CD81 antibodies [51].
To identify such MSC-sEV-specific antigens, the pre-
sence of MSC surface antigens in published MSC-(s)EV
proteome databases was recently investigated. These ana-
lyses revealed three MSC surface antigens from the ISCT
minimal criteria (CD73, CD90 and CD105), were found
in at least 7 of 10 publishedMSC-EV proteomics datasets,
while 3 non-MSC surface antigens from the ISCT mini-
mal criteria (CD14, CD34 and CD11b), were not found in
any of the 10 datasets [52]. Although the data are mostly
from BM-derivedMSCs (5 of 10), they also includeMSCs
derived from ESCs, placenta chorionic villi, CB, and AD
tissues. These findings support using the MSC positive
and negative surface antigens listed above to assess the
identity and purity of the cellular source of an MSC-sEV
preparation. Technically, the presence of MSC- and non-
MSC-sEVmarkers can be analysed by methods including
Western blotting, enzyme-linked immunosorbent assays,
classical flow cytometry of bead-captured EVs, or
advanced flow cytometry at the single EV level.
In summary, the MSC cellular origin of an sEV
preparation could be identified by the presence of
MSC markers, CD73, CD90 and CD105, and the
absence of CD14, CD34 and CD11b. It is, however,
recognized that it may not be practical for all MSC-sEV
preparations to be devoid of non-MSC markers, espe-
cially if the MSCs were cultured in the presence of
supplements such as hPL or serum. In the final analy-
sis, the relative abundance of MSC versus non-MSC
markers in an MSC-sEV population helps to assess
the relative ratio of MSC-sEV to non-MSC-sEVs and
will be useful in calibrating comparison between dif-
ferent MSC-sEV preparations.
When is a biological preparation an sEV, and not
a protein, RNA or lipid preparation?
Particle quantitation methods such as nanoparticle track-
ing analysis (NTA), dynamic light scattering (DLS), and
resistive pulse sensing (RPS) [53–57] are not specific to
EVs. There is increasing evidence that most particles in
many EV preparations are not in fact EVs. Thus, novel
EV identification and quantitation methods are required.
Since EVs are lipid membrane vesicles, an sEV prepara-
tion will be distinguished from more homogeneous pro-
tein, RNA, or lipid preparations by having membrane
lipids that are associated with proteins and/or RNAs.
Since the structure and size of sEVs are physically defined
by the lipid bilayer, the amount of RNA and/or protein
that can be accommodated within each EV is limited by
the amount of membrane lipids. Therefore, for specific
sEVs from a particular cell type, cultured under specified
conditions and separated by a specified protocol, the ratio
of membrane lipids to protein or RNA should be
a definitive, more quantifiable feature of the sEVs than
the numbers obtained by conventional particle analysis.
A comparison of sEV preparations and the produ-
cing cell is also instructive. Relative amounts of certain
lipids are different in MSC-sEV membranes versus the
bulk cellular membranes of the parent MSCs [reviewed
by [58]]. For example, the major plasma membrane
phospholipids, cholesterol, sphingomyelin and phos-
phatidylcholine, are enriched in the sEV membrane.
The proportion of sphingomyelin to phosphatidylcho-
line in sEV preparations was also reportedly twice as
high as in the corresponding cells [59]. It was also
observed that sEV preparations generally have an
8.4-fold enrichment of lipids per mg of protein com-
pared with cells [60].
To distinguish an sEV preparation from other bio-
logical nanoparticle preparations, the following quanti-
fiable metrics could be used:
a. ratio of specific membrane lipids to proteins
b. ratio of sphingomyelin to phosphatidylcholine
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What is the concentration of lipid membrane vesicles
in an sEV preparation?
In addition to the ratiometric approaches above, abso-
lute quantitation of sEVs might also be useful.
Unfortunately, with the exception of volumetric cryoe-
lectron microscopy (which also unambiguously reveals
lipid membrane vesicles), identifying particles as EVs is
difficult. Nevertheless, progress in single EV analysis by
methods such as fluorescence-augmented NTA or
nano-flow is promising to the extent that lipid and
protein labelling can be included [51,61–64].
What is the purity of the sEV preparation?
A pure sEV preparation might be defined as one in
which all proteins and RNA are anchored in or encap-
sulated within a lipid bilayer membrane. For sEVs with
a size range of 50–200 nm and a specific membrane
lipid to protein ratio, the number of sEVs would be
limited by the amount of membrane lipids or proteins.
Hence, if the number of sEVs is known and measured
as lipid membrane vesicles as discussed in question 3,
the number of sEVs per unit membrane lipids or
proteins would reflect the degree of purity. A caveat
is that a completely “pure” MSC-sEV preparation is not
likely to exist. Also, highly pure and concentrated EVs
without “carrier” materials might conceivably be lost
by binding to the surfaces of their containers.
Furthermore, loosely associated factors that contribute
to MSC-sEV biological activities might be removed by
stringent purification, resulting in a reduction or even
loss of therapeutic activities in the disease models of
interest. As there are presently no metrics to evaluate
the purity of an MSC-sEV preparation, a practical
alternative is to benchmark sEV preparations to
a universal MSC-sEV preparation. This universal MSC-
sEV preparation should be one that is manufactured
reproducibly on a large scale and with long-term
stability.
How to measure integrity of sEVs in a preparation?
EV integrity is synonymous with lipid membrane
integrity. Electron microscopy provides irrefutable evi-
dence for the presence of intact membrane vesicles but
is not high-throughput. Instead, membrane integrity
may be assayed using proteins that are tethered to
a membrane lipid, such as GM1 ganglioside. GM1
gangliosides are highly enriched in MSC-sEVs and are
bound with high affinity by cholera toxin B chain
(CTB) [65]. CTB-binding sEVs are also enriched in
CD81, and this association can be readily assayed by
ELISA. Disruption of vesicles by homogenization dis-
rupts the association between CD81 and CTB binding,
paralleled by loss of function [e.g. cardioprotective
activity [66]] and reduced CD81 in CTB-bound sEVs
(unpublished results, SKL). Thus, the level of CTB-
associated CD81 in a preparation provides a global
quantitative assessment of membrane integrity in an
sEV preparation [65] provided that the level of CTB-
CD81 for intact MSC-sEV can be established. In lieu of
this, the level of CTB-CD81 could be benchmarked
against a universally accepted MSC-sEV preparation.
CD81+ EVs might also be quantified by imaging flow
cytometry, plasmon resonance-based technologies, or
by novel, more sensitive fluorescence NTA
instruments.
What surrogates of cargo biological activity can be
measured?
Small EVs consist of and carry a diverse load of pro-
teins, lipids and RNA. The general consensus is that
upon reaching a target, the proteins and/or RNAs in
sEV preparations act as effector molecules either out-
side or inside the cell. Therefore, the protein and RNA
cargo in or on sEVs in general, or the MSC-sEVs
considered here, should be intact and not be degraded
or denatured if sEVs are to exert biological effects. To
assess if the cargo is generally intact, we propose mea-
suring the enzyme activity of a surface protein as
a surrogate of the integrity of the cargo. The enzymatic
activity of a protein is a function of its primary, sec-
ondary, tertiary and quaternary structures, and is pro-
portional to the integrity of these structures. Thus, the
biological integrity of an MSC-sEV preparation could
be assessed via surrogate proteins. One possible exam-
ple would be CD73, an ecto-5-prime-nucleotidase
(5-prime-ribonucleotide phosphohydrolase; EC
3.1.3.5) that converts AMP to adenosine, and this enzy-
matic activity can be easily assayed using commercially
available assay materials [65]. CD73 is also an MSC-
associated surface marker and one of the key MSC
markers of the ISCT minimal criteria. As a surface
protein, CD73 may be vulnerable to protein denatura-
tion and loss of enzyme activity. Thus, it might serve as
a sentinel to monitor the preservation of sEV cargo
functionality during preparation or storage. However,
cargo functionality may not depend on the integrity of
sEVs and may not be indicative of vesicle integrity.
Cargo functionality may not always be sufficient to
predict therapeutic activity, as therapeutic activity
may depend on many other factors, such as delivery
to the appropriate cell type, interaction of the cargo
with the appropriate subcellular compartments, and
the kinetics of cargo delivery.
Conceivably, RNA cargo and composition might
also be used to predict biological activity of an MSC-
sEV preparation. MicroRNAs in particular have been
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the focus of many EV RNA studies, with evidence that
EV miRNAs are highly stable and can be transferred
into and function in recipient cells [67]. However,
detection of a mature miRNA alone might not equate
with canonical, RNA-induced silencing complex
(RISC)-associated function, as the miRNA (like an
siRNA) must be incorporated into the RISC machinery
of the recipient cell to be functional [68]. This loading
occurs during processing of the pre-miRNA form, and
dissociation of mature miRNA from RISC components
during the sEV harvest or purification process might
render the miRNA non-functional. Therefore,
a miRNA-based surrogate assay for MSC-sEV activity
should assay mature miRNA association with RISC
components (e.g. Argonaute) or examine the presence
and activity of pre-miRNA. However, there may be
non-canonical actions of miRNAs that such assays
would not reflect.
Conclusions and action plan
A key confounding factor in MSC-sEV research and
translation is the wide variability in MSC-sEV prepara-
tions that permeates the entire process from the start-
ing producer cell source through the production and
purification to the final product. This, coupled with the
lack of standardized quality assurance assays and
in vitro and in vivo functional assays, has led to dis-
crepancies and controversies about the biology, func-
tions, and therapeutic potency of MSC-sEVs. While
defining a biological product by its manufacturing pro-
cess is an accepted practice in early stage clinical
research, defining MSC-sEV products by the process
is not recommended for advancing the science and
later-stage clinical applications of MSC-sEVs. This
approach could lead to overclassification of MSC-
sEVs and hinder data sharing or comparison among
different research groups. Furthermore, there is pre-
sently no consensus on the best way to produce ther-
apeutically active MSC-sEVs, particularly as these have
not yet been strictly defined and tested for clinical
indications.
A more practical approach would be to develop a set
of minimal quantifiable metrics to harmonize the defi-
nition of MSC-sEVs and provide a denominator for
comparative manufacturing and functional testing of
different preparations (please refer to checklist). This
will facilitate data sharing or comparison among MSC-
sEV preparations as differences in biology or therapeu-
tic applications could be mapped to quantifiable differ-
ences in the defining features.
Here, we have identified potential metrics of MSC-
sEVs, namely the ratio of MSC to non-MSC surface
antigens, ratio of membrane lipids to protein, ratio of
specific lipids, concentration of membrane lipid vesicles,
vesicle integrity, and biological activity. The next step will
be to quantify and validate each metric. One practical
approach is to use a well-characterized MSC-sEV pre-
paration as reference for each metric and to have each
metric assessed by several independent laboratories to
ensure the robustness and reproducibility of the metric
assays. In assessing the metrics, reagents for a phenotypic
and a functional assay, if not commercially available,
should be shared or bought from the same supplier for
distribution to all. The evaluating teams will compare
their own MSC-sEVs with the reference sample utilizing
their in-house assays as well as the shared assays. Results
will be collected, analysed, and discussed. If positively
evaluated, strategies for producing reference samples
and phenotypic/functional assays for the community of
MSC-EV researchers will be developed. This spirit of
collaboration is necessary and desirable in promoting
MSC-sEV research and applications.
Future perspectives
In this exercise, we have focused on identifying the key
defining physical and biological characteristics of MSC-
sEVs, and on developing assays to measure these char-
acteristics. The underlying assumption is that these
characteristics are ultimately crucial to the therapeutic
potency of the sEV preparations. However, these char-
acteristics convey only the physical and biological
integrity of EVs and may not predict therapeutic
potency. Therefore, the immediate next challenge will
be to develop assays that predict the therapeutic
potency of MSC-EVs in quantifiable, robust, and
reproducible parameters. Based on the complexity of
MSC-sEV preparations and the wide spectrum of dis-
eases against which they have been reported to be
efficacious, the therapeutic mode of action will likely
be different and specific for each disease condition. In
addition to the mode of action, the therapeutic potency
of MSC-sEV will also be influenced by an agonistic or
antagonistic disease microenvironment, delivery route,
and time window for therapeutic intervention for
a particular disease. Establishing appropriate functional
assays to measure therapeutic activity will also require
a deep understanding of MSC-sEV biology, e.g. the
half-life and in vivo biodistribution of MSC-sEVs in
a normal and diseased state and knowledge of direct
and indirect target cells in different tissues. Therefore,
defining the therapeutic potency of MSC-sEV prepara-
tions will require another level of discussion and will be
the topic of future activities of SOCRATES, ISCT,
ISEV, and ISBT.
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Note
1. (https://clinicaltrials.gov/ct2/results?cond=&term=
mesenchymal+cells&cntry=&state=&city=&dist=
&Search=Search Search conducted 2018–12-05, results =
964).
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